Related Experiment Video
Updated: Jul 7, 2026
Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Towards a better understanding and new therapeutics of osteopetrosis
Maria K Askmyr1, Anders Fasth, Johan Richter
1Department of Molecular Medicine and Gene Therapy, Lund University, Lund, Sweden.
Abstract:
Lack of or dysfunction in osteoclasts result in osteopetrosis, a group of rare but often severe, genetic disorders affecting skeletal tissue. Increase in bone mass results in skeletal malformation and bone marrow failure that may be fatal. Many of the underlying defects have lately been characterized in humans and in animal models of the disease. In humans, these defects often involve mutations in genes expressing proteins involved in the acidification of the osteoclast resorption compartment, a process necessary for proper bone degradation. So far, the only cure for children with severe osteopetrosis is allogeneic hematopoietic stem cell (HSC) transplantation but without a matching donor this form of therapy is far from optimal. The characterization of the genetic defects opens up the possibility for gene replacement therapy as an alternative. Accordingly, HSC-targeted gene therapy in a mouse model of infantile malignant osteopetrosis was recently shown to correct many aspects of the disease.
Insights
Osteopetrosis, a rare genetic bone disorder, stems from osteoclast dysfunction. Gene therapy targeting hematopoietic stem cells (HSCs) shows promise in correcting this skeletal tissue disease.
Area of Science:
- Genetics
- Skeletal Biology
- Cell Biology
Background:
- Osteopetrosis is a group of rare, severe genetic disorders characterized by defective osteoclast function, leading to increased bone mass, skeletal malformations, and potentially fatal bone marrow failure.
- Genetic defects in humans often involve impaired acidification of the osteoclast resorption compartment, crucial for bone degradation.
- Current treatment for severe infantile osteopetrosis relies on allogeneic hematopoietic stem cell (HSC) transplantation, which has limitations, especially without a matched donor.
Purpose of the Study:
- To explore gene replacement therapy as an alternative treatment for osteopetrosis.
- To evaluate the efficacy of HSC-targeted gene therapy in a preclinical model of infantile malignant osteopetrosis.
Main Methods:
- Characterization of genetic defects underlying osteopetrosis in humans and animal models.
- Development and application of HSC-targeted gene therapy.
- Assessment of disease correction in a mouse model of infantile malignant osteopetrosis.
Main Results:
- Identification of genetic mutations affecting osteoclast acidification as a cause of osteopetrosis.
- Successful correction of multiple disease aspects in a mouse model using HSC-targeted gene therapy.
- Demonstration of the therapeutic potential of gene therapy for osteopetrosis.
Conclusions:
- Genetic defects in osteoclast function are central to osteopetrosis pathogenesis.
- HSC-targeted gene therapy represents a promising alternative to HSC transplantation for treating severe osteopetrosis.
- Further development of gene replacement strategies could offer a curative approach for osteopetrosis patients.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...